PBGH Announcements

For Media Inquiries:

Lisa Zamosky
(917) 751-0232
lzamosky@pbgh.org


December 23, 2020

PBGH Statement on Legislation Aimed at Lowering Drug Costs

PBGH applauds initiatives by Speaker Nancy Pelosi and other members of the House leadership to reduce prescription drug costs.  Read […]

December 23, 2020

PBGH Pushes for Lower Health Care Costs

Elizabeth Mitchell sent a letter to the Senate HELP Committee on Tuesday, following her influential testimony at the Committee’s hearing on June 18.  She continued to push for an end to surprise billing (including air ambulances), a reasonable benchmark for physician payments, reductions in drug costs, prohibitions on anti-competitive provider contracting terms, increased transparency (including for PBMs), and improvements in maternal and child health.  The bill is under active consideration by the Committee, and a final version will be made public soon.

December 23, 2020

Elizabeth Mitchell testified before 6/18 Senate HELP Committee

Read and listen to PBGH President and CEO Elizabeth Mitchell’s testimony before the U.S. Senate HELP Committee on June 18th and hear her share how care should and can be high quality and affordable.

December 23, 2020

Mental Health is Bigger than Mental Health, PBGH & IBI Regional Forum

The Pacific Business Group on Health and The Integrated Benefits Institute held a daylong symposium on high-value innovations by large employers and key stakeholders to improve behavioral health care, access, employee experience and outcomes.

December 23, 2020

Energy and Commerce Committee‘s Draft Legislation Will Provide Critical Protection for Consumers from Surprise Medical Bills

Members of PBGH join other employers and healthcare purchasers to stop the unfair and harmful surprise billing that takes place due to no fault of patients accessing healthcare that they believe is in-network, or for which they have no choice.  Read more here. 

December 23, 2020

PBGH & Leapfrog Announce 2018 Top Hospital Award for California Hospitals

PBGH and The Leapfrog Group, a national nonprofit aiming to improve health care quality for consumers and purchasers, announced 17 California have been named to its 2018 national list of Top Hospitals. 

December 4, 2020

EmployersRx calls on Congress and industry to ensure fair and reasonable pricing for COVID-19 vaccines and therapeutic drugs.

As the COVID-19 crisis will only end when people have access to effective vaccines and therapeutic drugs, EmployersRx urges legislators, manufacturers and providers to ensure fair and reasonable pricing of these shortly anticipated treatments.

July 23, 2020

Senate Republicans Introduce “Phase 4” Coronavirus Response Bill

On Monday evening, Senate Majority Leader Mitch McConnell (R-KY) announced introduction of the Health, Economic Assistance, Liability Protection and Schools (HEALS) Act, a roughly $1 trillion package responding to the ongoing COVID-19 pandemic. Introduction of the bill came after difficult negotiations between Senate Republicans and the White House, which delayed introduction by roughly one week. In May, the House passed the competing $3 trillion Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act along party lines. Now the two sides will begin what are expected to be tough and protracted negotiations to reach a final agreement.

July 22, 2020

PBGH joins others to offer Congress policy recommendations

PBGH joined 30 other organizations representing many of the nation’s leading private and public sector employers to offer Congress specific recommendations for health coverage-related policies to be included in the forthcoming legislation

July 21, 2020

PBGH urges Congress to fund robust COVID-19 testing

PBGH, along with other organizations representing many of the nation’s leading employers, is urging Congress to support the efforts of employers to return their employees to work safely by investing additional federal resources in the robust testing needed to accomplish both the public health and economic goals, and to ensure that employers and taxpayers are not subject to opaque and exorbitant prices for COVID-19 tests and associated services.